Boston Common Asset Management’s Dr. Reddy's Laboratories RDY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $772K | Hold |
53,275
| – | – | 0.05% | 150 |
|
|
2026
Q1 | $738K | Hold |
53,275
| – | – | 0.05% | 148 |
|
|
2025
Q4 | $748K | Hold |
53,275
| – | – | 0.05% | 155 |
|
|
2025
Q3 | $745K | Hold |
53,275
| – | – | 0.02% | 256 |
|
|
2025
Q2 | $801K | Hold |
53,275
| – | – | 0.02% | 259 |
|
|
2025
Q1 | $703K | Buy |
53,275
+35,210
| +195% | +$486K | 0.02% | 258 |
|
|
2024
Q4 | $285K | Buy |
18,065
+3,140
| +21% | +$47.2K | 0.01% | 283 |
|
|
2024
Q3 | $237K | Hold |
14,925
| – | – | 0.01% | 301 |
|
|
2024
Q2 | $227K | Sell |
14,925
-91,965
| -86% | -$1.32M | 0.01% | 305 |
|
|
2024
Q1 | $1.57M | Hold |
106,890
| – | – | 0.04% | 262 |
|
|
2023
Q4 | $1.49M | Buy |
106,890
+14,450
| +16% | +$193K | 0.03% | 260 |
|
|
2023
Q3 | $1.24M | Buy |
92,440
+8,675
| +10% | +$117K | 0.03% | 255 |
|
|
2023
Q2 | $1.06M | Hold |
83,765
| – | – | 0.02% | 257 |
|
|
2023
Q1 | $954K | Hold |
83,765
| – | – | 0.02% | 256 |
|
|
2022
Q4 | $867K | Hold |
83,765
| – | – | 0.04% | 171 |
|
|
2022
Q3 | $877K | Sell |
83,765
-19,970
| -19% | -$213K | 0.05% | 169 |
|
|
2022
Q2 | $1.15M | Buy |
103,735
+26,770
| +35% | +$291K | 0.06% | 167 |
|
|
2022
Q1 | $858K | Buy |
76,965
+1,975
| +3% | +$22.4K | 0.04% | 177 |
|
|
2021
Q4 | $981K | Buy |
74,990
+17,500
| +30% | +$221K | 0.04% | 175 |
|
|
2021
Q3 | $749K | Buy |
57,490
+10,350
| +22% | +$138K | 0.03% | 182 |
|
|
2021
Q2 | $693K | Sell |
47,140
-10,360
| -18% | -$145K | 0.03% | 195 |
|
|
2021
Q1 | $706K | Buy |
+57,500
| New | +$739K | 0.04% | 186 |
|
|
2020
Q2 | – | Sell |
-81,360
| Closed | -$656K | – | 220 |
|
|
2020
Q1 | $656K | Hold |
81,360
| – | – | 0.09% | 157 |
|
|
2019
Q4 | $660K | Buy |
81,360
+3,360
| +4% | +$26.5K | 0.08% | 167 |
|
|
2019
Q3 | $591K | Hold |
78,000
| – | – | 0.07% | 156 |
|
|
2019
Q2 | $585K | Buy |
78,000
+6,050
| +8% | +$47.6K | 0.07% | 159 |
|
|
2019
Q1 | $583K | Hold |
71,950
| – | – | 0.08% | 155 |
|
|
2018
Q4 | $543K | Buy |
71,950
+10,850
| +18% | +$76.3K | 0.08% | 147 |
|
|
2018
Q3 | $423K | Hold |
61,100
| – | – | 0.05% | 168 |
|
|
2018
Q2 | $393K | Buy |
+61,100
| New | +$385K | 0.05% | 165 |
|
|
2014
Q3 | – | Sell |
-1,125
| Closed | -$10K | – | 306 |
|
|
2014
Q2 | $10K | Hold |
1,125
| – | – | ﹤0.01% | 337 |
|
|
2014
Q1 | $10K | Buy |
+1,125
| New | +$9.79K | ﹤0.01% | 371 |
|
|
2013
Q4 | – | Sell |
-1,125
| Closed | -$9K | – | 342 |
|
|
2013
Q3 | $9K | Hold |
1,125
| – | – | ﹤0.01% | 387 |
|
|
2013
Q2 | $9K | Buy |
+1,125
| New | +$8.21K | ﹤0.01% | 370 |
|
Other funds holding RDY
AIM
Boston Common Asset Management's RDY Position: Q2 2026 in Review
Boston Common Asset Management held its Dr. Reddy's Laboratories (RDY) position steady in Q2 2026 at 53,275 shares worth $772K. The position accounts for 0.05% of the portfolio, ranked #150.
Boston Common Asset Management first reported a position in RDY in Q2 2013 and has held it in 34 quarters since. The position peaked at $1.57M in Q1 2024. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.
- Boston Common Asset Management held 53,275 shares of Dr. Reddy's Laboratories worth $772K as of Q2 2026.
- Boston Common Asset Management left its Dr. Reddy's Laboratories share count unchanged in Q2 2026.
- Dr. Reddy's Laboratories made up 0.05% of Boston Common Asset Management's portfolio in Q2 2026, its #150 holding.
- Boston Common Asset Management first reported a position in Dr. Reddy's Laboratories in Q2 2013 and has held it in 34 quarters since.
- Boston Common Asset Management's Dr. Reddy's Laboratories position peaked at $1.57M in Q1 2024.
- 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.
Based on Boston Common Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.